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Abstract
Genetic researchers often collect disease related quantitative traits in addition to disease status because they are
interested in understanding the pathophysiology of disease processes. In genome-wide association (GWA) studies, these
quantitative phenotypes may be relevant to disease development and serve as intermediate phenotypes or they could be
behavioral or other risk factors that predict disease risk. Statistical tests combining both disease status and quantitative
risk factors should be more powerful than case-control studies, as the former incorporates more information about the
disease. In this paper, we proposed a modified inverse-variance weighted meta-analysis method to combine disease
status and quantitative intermediate phenotype information. The simulation results showed that when an intermediate
phenotype was available, the inverse-variance weighted method had more power than did a case-control study of
complex diseases, especially in identifying susceptibility loci having minor effects. We further applied this modified meta-
analysis to a study of imputed lung cancer genotypes with smoking data in 1154 cases and 1137 matched controls. The
most significant SNPs came from the CHRNA3-CHRNA5-CHRNB4 region on chromosome 15q24–25.1, which has been
replicated in many other studies. Our results confirm that this CHRNA region is associated with both lung cancer
development and smoking behavior. We also detected three significant SNPs—rs1800469, rs1982072, and rs2241714—in
the promoter region of the TGFB1 gene on chromosome 19 (p = 1.4661025, 1.1861025, and 6.5761026, respectively). The
SNP rs1800469 is reported to be associated with chronic obstructive pulmonary disease and lung cancer in cigarette
smokers. The present study is the first GWA study to replicate this result. Signals in the 3q26 region were also identified in
the meta-analysis. We demonstrate the intermediate phenotype can potentially enhance the power of complex disease
association analysis and the modified meta-analysis method is robust to incorporate intermediate phenotype or other
quantitative risk factor in the analysis.
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Introduction
Genome-wide association (GWA) studies have identified hun-
dreds of common genetic variants associated with complex
diseases and provided valuable insight into their genetic architec-
ture. However, most of these variants confer relatively low risk
effects and explain only a small proportion of the heritability of
most complex diseases. For most of these diseases, less than 10% of
the genetic variance is explained by the identified common
variants, leaving the bulk of heritability unexplained [1]. One
important reason for the unexplained heritability is that most of
the genetic variants that have been identified have small odds
ratios (around 1.1 for the heterozygous genotypes and 1.5–1.6) for
the homozygous genotypes; latent variants likely have even less of
a disease effect [2]. Researchers estimated that hundreds of genetic
variants are involved in the development of complex diseases but
that together they would explain only about 20% of genetic
variance [3]. Investigators have used imputation of genetic loci
from the Hapmap and other referent populations to boost the
power of case-control association studies for complex diseases [4–
5]. However, traditional case-control studies still have limited
power to detect genetic variants with low risk effect so new
statistical analysis methods are needed in the study.
Disease status is often the ultimate result of influences from
multiple genotypes and environmental factors. Many ‘‘intermedi-
ate’’ phenotypes reflect the pathway leading to disease develop-
ment. An intermediate phenotype may reflect more directly the
effects from causal genes than disease status and be less genetically
complex and more strongly associated with susceptibility loci.
Analysis of intermediate phenotypes has the potential to capture
the underlying heritable trait variation that may be missed in case-
control studies, thus increasing the statistical power in genetic
association studies [6–7]. Studying intermediate phenotypes would
also provide insight into the complicated etiologic disease
pathways. Behavioral and other quantitative measures of increased
risk for disease may also help to improve the power of studies to
detect associations of genetic factors with disease risk if these
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behavioral or other risk factors involve the same genetic factors in
their etiology as the disease.
Intermediate phenotypes, also known as endophenotypes, were
first used in psychiatric disorders studies as they were easier to
measure and less complicated than disease status [6]. Endophe-
notypes have been successfully applied in unraveling the complex
etiology of mental disease. For example, neurological soft signs
have been used as an endophenotype in analysis of Schizophre-
nia. In 2012, Greenwood et al. [8] found 94 candidate genes
associated with Schizophrenia-relate endophenotypes. Simons et
al. [9] identified VMAT2 as a candidate gene for psychotic
disorder and neurocognition using measurement of cognitive
functioning as the intermediate phenotype. Researchers also have
adapted endophenotype for use in other complex disease studies.
For example, high mammographic density is one of the strongest
known risk factors for breast cancer and is an intermediate
phenotype that can help elucidate the genetic factors that
contribute to development of breast cancer [10]. In 2011,
researchers identified the gene ZNF365 on chromosome 10 as
being associated with both breast cancer and mammographic
density [11]. That same year, researchers used neuropathology
and cognitive function proximate to death as the intermediate
phenotypes for Alzheimer disease and identified two genes—
ZNF224 and PCK1—involved in the development of Alzheimer
disease [12]. In these two studies, the researchers performed
linear regression analysis of the quantitative intermediate
phenotype with the marker genotype as the covariates. Their
findings suggested successful use of intermediate phenotypes in
genetic association analysis of complex diseases.
Meta-analysis is a powerful method in GWA studies, as it can
combine information from independent populations, thus in-
creasing the sample size and overcoming the lack of power in
most common disease studies [13–16]. The combined informa-
tion from multiple populations is either disease status or
quantitative trait, not both of them. The most widely used
meta-analysis techniques are Fisher’s combined probability test
[17] and inverse-variance weighting [18]. When intermediate
phenotypes and disease status are both available in a study, a
meta-analysis method combining disease status and intermediate
phenotypes should be more powerful than either a case-control
study or linear regression analysis of quantitative traits alone, as
meta-analysis incorporates more information from the patients.
In the present study, we demonstrated that meta-analysis can be
used to examine a combination of the disease status and
intermediate phenotype information from a single population in
a complex disease study and a modified inverse-variance
weighted method was proposed for the analysis. Simulation was
conducted to evaluate the performance of Fisher’s combined
probability test, the modified inverse-variance weighted method,
and the traditional case-control method. The results showed that
inverse-variance weighting was the best of the three methods. We
then applied the meta-analysis to a study of imputed lung cancer
genotypes with smoking data. The results validated previous
findings regarding the CHRNA3-CHRNA5-CHRNB4 region on
chromosome 15q24–25.1 [19–23] and the promoter region of the
TGFB1 gene on chromosome 19 [24–25], which suggested the
modified inverse-variance weighting was a reliable method to do
the meta-analysis within a study. A new region—3q26.1—was
also identified; no genes are located in this region, and deletion of
the region has been reported to be associated with some cancers
[26–27].
Results
Simulation study of the novel method for combining
results from disease and intermediate phenotype
association studies
Table 1 lists the parameters for the medium- and low-risk
susceptibility loci in simulations. The results for the medium- and
low-risk variants are shown in Figures 1 and 2. The x-axis in each
graph denotes the correlation coefficient between the SNP marker
and disease locus, which increased from 0 to 0.8. The y-axis in
each graph denotes the power of each test. When the SNP marker
was directly associated with the disease status but the disease-
related quantitative trait was not associated with the SNP marker
of interest, we obtained no useful information about the
quantitative trait pertaining to the SNP marker studied (lines 1,
3, and 5 in Figures 1–2). Logistic regression analysis was the most
powerful method to detect the association between the SNP
marker and disease status followed by Fisher’s combined
probability test. The power of modified inverse-variance weighted
method was only about half of that of logistic regression. When the
quantitative trait was an intermediate phenotype between the SNP
marker and disease status, linear regression analysis of the
quantitative trait provided valuable information for the association
analysis. The power of the tests increased as the correlation
coefficient between the SNP marker and disease locus increased (x-
axis). Also, as the heritability of the quantitative trait explained by
the SNP increased from 0.002 to 0.010 (columns 1–5 in Figures 1–
2), the power of the linear regression analysis increased, as did the
power of the meta-analysis methods, because they rely on the
information from linear regression analysis. The modified inverse-
variance weighted method was more powerful than Fisher’s
combined probability test in the meta-analysis (lines 2, 4, and 6 in
Figures 1–2). Using the recessive model, logistic regression analysis
had little power, and the linear regression analysis had the
predominant effect in the meta-analysis. The performance of
Fisher’s combined probability test and the modified inverse-
variance weighted method were almost equal to that of the linear
regression analysis.
The type I error rate in this simulation was set at 0.01. To
obtain an accurate estimation of the type I error rate, we carried
out 10,000 simulations for each set of conditions under the null
hypothesis of no association between the SNP marker and disease
locus. We did not observe an inflated type I error rate in this
simulation for any of the methods (Table S1 and S2).
Application of the modified inverse-variance weighted
meta-analysis method to imputed lung cancer
genotypes with smoking data
The 2log10(p)s for logistic regression analysis of disease status,
linear regression analysis of cigarettes per day (CPD) with
adjustment for disease status, Fisher’s combined probability test,
and our modified inverse-variance weighted method are plotted in
Figure 3. The SNPs with 2log10(p)s greater than 5 are highlighted
as the SNPs potentially associated with lung cancer. Although the
SNPs do not meet the commonly accepted criterion of
2log10(p).8 because of our limited sample size, they are still
very promising signals that can be further validated. The inflation
factors l in the tests were ranged from 1.01–1.02, indicating no
spurious association caused by population stratification in the
analyses. Consecutive significant SNPs in a chromosomal region
are listed in Table S3, and we identified three significant regions in
our meta-analysis. The most significant region was AGPHD1-
CHRNA3-CHRNA5-CHRNB4 on chromosome 15q24–25.1
Joint Genetic Association with Disease and Trait
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(Figure 4). When we used a traditional case-control method, no
SNP in this region had a 2log10(p) greater than 5 because of the
limited sample size. In the meta-analysis, this region became very
significant with the strongest signal at rs12914385 with a p-value
1.9861029. This result confirmed that the CHRNA3-A5 region on
15q24–25.1 is associated with both lung cancer development and
smoking behavior, which several other independent studies have
already proven [19–23], and that CPD is an intermediate
phenotype for lung cancer.
Another significant region is the B9D2 gene, which encodes a
protein that lies partially within the TGFB1 promoter on
chromosome 19 [28]. SNP rs1800469, rs1982072, and
rs2241714 had a p value less than 0.001 in our case-control study
and less than 0.01 in quantitative trait analysis. In the modified
inverse-variance weighted meta-analysis, these three SNPs had a
p-value of 1.4661025, 1.1861025, and 6.5761026, respectively.
Previous authors reported that the SNPs rs1800469 and
rs2241712 in the promoter of the TGFB1 gene are associated
with chronic obstructive pulmonary disease and lung cancer in
cigarette smokers [24–25]. Our results supported the signal at
rs1800469; rs2241712 was not present in our genotype data, but
rs2241714 (about 350 bp away from rs2241712) was also
significant (Table S3). The evidence from a GWA study supports
that the TGFB1 gene is associated with tobacco-induced lung
cancer. The significant SNPs in the TGFB1 promoter region may
be related to abnormal TGFB1 gene transcription levels in lung
cancer patients. We also identified a large region on 3p26 (4.139–
4.258 Mb) associated with both lung cancer development and
smoking behavior, a total of 74 SNPs with a p-values around
1.061025 were detected, and only two of them were from the
genotyped SNPs, they were rs1444056 (4214953 bp) and
rs1403124 (4188033 bp). No genes with known functions reside
in this region although deletion of the region has been reported to
be associated with some cancers [26–27].
For the significant SNPs identified in the three regions, the
modified inverse-variance weighted method always produced a
stronger signal than did Fisher’s combined probability test. To
further compare the performance of Fisher’s combined probability
test and the modified inversed-variance weighted method in
association analysis, we plotted the 2log10(p) in the case-control
method versus Fisher’s combined probability test, and the case-
control method versus the inverse-variance weighted method
(Figure 5). The plot on the left in the figure shows that Fisher’s
combined probability test tended to produce more significant
signals for non-significant SNPs (2log10(p),4) in the case-control
study, which may have introduced a higher false-discovery rate
than the inverse-variance weighted method in real data analysis.
The reason for this finding is that Fisher’s combined probability
test is based on the p values from the logistic and linear regression
tests, and so cannot tell the directions of the association effect from
these two regression tests. Fisher’s combined probability test can
produce a significant result even when the effects in logistic and
linear regression analyses are in opposite directions. This should
not be true when the quantitative trait is an intermediate
Figure 1. Power Plots for the Medium-Risk Model.
doi:10.1371/journal.pone.0046612.g001
Joint Genetic Association with Disease and Trait
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phenotype for the disease being studied. The modified inverse-
variance weighted method does not have this problem because it is
based on linear combination of the two effect sizes. Therefore, it is
a better method than Fisher’s test for a single- population meta-
analysis.
Discussion
Researchers have widely used meta-analysis in genetic associ-
ation studies to combine information from different populations
and increase sample sizes. However, it is rarely used to combine
different types of data in a single population. Genetic researchers
will often collect phenotypic information in addition to disease
status to better understand the pathophysiology of disease
development and to maximize study findings; in many of these
instances, the information is on intermediate phenotypes. A meta-
analysis method incorporating both the disease status and
intermediate phenotype should be more powerful than a
traditional case-control study method. In the present study, we
examined a modified inverse-variance weighted meta-analytical
method. Simulation studies showed that this method is more
powerful than the traditional case-control method in association
analysis of complex diseases, especially for identification of disease
loci having very minor effects. Also, compared with Fisher’s
combined probability test, inverse-variance weighted meta-analy-
sis is more robust as it has a bigger power and a lower type I error
Figure 2. Power Plots for the Low-Risk Model.
doi:10.1371/journal.pone.0046612.g002
Table 1. Parameters for Medium- and Low-Risk Models in
simulation.
Genetic
Model b1 c0 c1 ODhetero ODhomo
Medium Add1
a 0 23.36 log1.20 1.20 1.44
Add2
b 1 23.1 log1.15 1.20 1.43
Dom1 0 23.36 log1.14 1.30 1.30
Dom2 1 23.16 log1.07 1.31 1.31
Rec1 0 23.13 log1.14 1.00 1.30
Rec2 1 23.04 log1.07 1.00 1.31
Low Add1 0 23.16 log1.10 1.10 1.21
Add2 1 23.05 log1.05 1.10 1.22
Dom1 0 23.18 log1.08 1.17 1.17
Dom2 1 23.07 log1.04 1.17 1.17
Rec1 0 23.05 log1.08 1.00 1.17
Rec2 1 23.00 log1.04 1.00 1.17
ODhetero: odds ratio for heterozygous genotypes; ODhomo: odds ratio for
homozygous genotypes; Add: additive; Dom: dominant; Rec: recessive.
aDisease model 1 in Figure 1–2.
bDisease model 3 in Figure 1–2.
doi:10.1371/journal.pone.0046612.t001
Joint Genetic Association with Disease and Trait
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rate. We set the MAFs of the SNP marker and disease locus as
equal in our simulation studies and we observed that the results of
the tests were similar when the MAFs were set differently (results
not shown). In addition, the intermediate phenotypes in both
patients and controls were available in this study. This phenotype
is sometimes only available in patients because either the
quantitative trait is expressed in them only or the cost of
measuring the quantitative trait in controls is too high. Our
simulation study showed that the meta-analysis was still better than
the case-control study method when the quantitative trait was only
available for patients (results not shown).
We further applied meta-analysis to empirical data analysis.
Smoking behavior, which can be quantified as smoking duration
or smoking quantity, is the most important risk factor for lung
cancer development. In 2008, several replicated studies showed
that there was a strong association between the nicotinic
acetylcholine receptor subunit cluster of genes (CHRNA) on
chromosome 15q25.1 and lung cancer. But there was no
conclusion on whether the association was direct or mediated
via smoking behavior. Hung’s group [23] observed an increased
risk even in non-smokers, which implied at least some of the risk
was not mediated via smoking. Thorgeirsson et al. [29] suggested
that the association with lung cancer was mainly mediated through
smoking behavior. In 2010, researchers using genome-wide
approaches provided conclusive evidence for a strong association
between CHRNA genes and smoking behavior [22]. There is
reason to believe that CHRNA genes are associated with both
smoking and lung cancer. Smoking behavior is an attribute
associating with increased lung cancer risk. The method that we
derive can be applied equally well to either intermediate
phenotypes or to behavioral attributes that associate with
increased risk for a disease. To address this comment, we revised
our paper by inserting discussion about modeling either interme-
diate phenotypes or other quantitative risk factors into the model.
The GWA study incorporating the quantitative trait of CPD with
the imputed genotype data detected significant SNPs on chromo-
somes 3, 15, and 19. The signal in the CHRNA3-CHRNA5-
CHRNB4 region was much stronger in the meta-analysis than in
the case-control study. The highest p value was 1.9861029, which
was a very strong signal in our small sample size (1154 cases and
1146 controls). Many independent studies have replicated the
finding of association of CHRNA3-CHRNA5-CHRNB4 on 15q24
with lung cancer and smoking behavior. Our results further
confirmed this finding. Also, it suggested that CPD is abehaviorally
mediated risk factor for lung cancer or an intermediate phenotype
that is involved in lung cancer risk. Whether or not the genetic
effects of the nicotinic receptor variants on chromosome 15q25.1
directly contribute to lung cancer risk or only contribute through
their effects on smoking behavior is a topic of ongoing debate and
further study. Mediation analyses [30–31] have shown both direct
and indirect (through smoking behavior) effects of the SNPs in this
region on lung cancer risk. In contrast, a study of the SNP effects
on cigarette per day use versus cotinine levels among smokers
shows a much stronger effect on cotinine levels [32–33]. This
finding suggests that reported cigarettes per day is inadequately
capturing the actual exposure individuals experience to nicotine,
but this observation still does not indicate yet the exact pattern of
relationship of the genetic effects on smoking versus lung cancer
risk [34].
The SNPs rs1800469 and rs2241712 in the promoter of the
TGFB1 gene on chromosome 19 were associated with chronic
obstructive pulmonary disease and lung cancer in smokers in
previous studies. These polymorphisms can only be detected in our
study using meta-analysis. Thus, meta-analysis combining an
intermediate phenotype and the disease status is a powerful tool
for detecting genetic variants in complex disease association
studies, especially when the effects of the susceptibility loci are
minor. The significant SNPs detected in these verified regions
demonstrate that our modified inverse-variance weighted meta-
Figure 3. Manhattan Plot of GWA Studies of Lung Cancer and CPD Data. 1–4: case-control method (l= 1.018), linear regression analysis with
adjustment for disease status (l= 1.010), Fisher’s combined probability test (l= 1.013), and the modified inverse-variance weighted method
(l= 1.011). 2log10(p).4.5 was used as the cutoff in plot 1 to match with the previous GWA study published in 2008 (Nat Genet, 40.5: 616–622).
2log10(p).5 was used as the cutoff in plot 2–4 to reduce false discovery rate.
doi:10.1371/journal.pone.0046612.g003
Joint Genetic Association with Disease and Trait
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Figure 4. 2Log10(P) Plot of Significant SNPs on Chromosomes 3, 15, and 19 in Meta-analysis of imputed lung cancer genotypes
with smoking data.
doi:10.1371/journal.pone.0046612.g004
Figure 5. P-Value Comparisons between the tests. X-axis, 2log10(p) from logistic regression analysis. Y-axis, 2log10(p) from Fisher’s combined
probability test (left); 2log10(p) from the modified inverse-variance weighted method (right).
doi:10.1371/journal.pone.0046612.g005
Joint Genetic Association with Disease and Trait
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analysis is a reliable method for genetic association studies when
an intermediate phenotype is available.
In the lung cancer study, the intermediate or behaviorally
related phenotype, smoking quantity, has a positive relationship
with disease status. This positive correlation may not always be
true. For example, there is a negative relationship between brain
size and Alzheimer’s disease. In this case, the quantitative trait can
be specified as the measurement of the overall brain shrinkage
from the patient’s normal brain size, which has a positive
relationship with the disease. Researchers may use prior studies
to assess correlations between the intermediate phenotype and the
disease of interest to help determine how this information should
be combined in the joint analysis.
In this study, the modified inverse-variance based test was
applied when only one intermediate phenotype is available.
Statistically, it can also be applied when multiple intermediate
phenotypes are available in the data as this method is based on the
combination of estimators from several regression tests with the
modified inverse variance as the weights. However, consideration
is needed on the complicated disease model when multiple
intermediate phenotypes are existent. The disease model could
include multiple disease pathways with each one having an
intermediate phenotype in it, or one pathway with more than one
intermediate phenotypes in it, or even a mixture of them. Further
investigation is needed for the application of this method in a more
complicated situation.
Whereas an intermediate phenotype is very useful in GWA
studies, it also has potential to help researchers understand the
intricate interactions among the disease associated genes and
elucidate the complicated mechanism underlying the human
diseases. The rapid development of microarray technology has
made genome-wide gene expression profiles available to research-
ers. The gene expression levels are closely linked with both the
genetic variants and disease status, providing a large number of
intermediate phenotypes for complex diseases. Meta-analysis
combining the disease status and gene expression data will be
very powerful in identifying the functional genetic variants
associated with complex diseases. This modified inverse-variance
weighted meta-analytic approach is a promising tool in decipher-
ing complex disease codes.
Materials and Methods
Simulation study
Given a disease locus A having two alleles A1 and A2 with allele
frequencies q1 and q2 (q1+q2 = 1), an SNP marker M has two alleles
M1 and M2 with allele frequencies m1 and m2 (m1+m2 = 1). The
SNP marker and disease locus are closely linked so that they are in
linkage disequilibrium, which can be quantified using the correla-
tion coefficient (r). The pathway to a complex disease has an
intermediate phenotype that can be measured as a quantitative trait
(Y). If X denotes the genotype at the SNP marker, then the
relationship between Y and X can be expressed using the linear
equation Y =b0+b1X+e, in which e represents the error term
following N(0,s2E). The genotypes at X were coded as 0, 1, and 2
for an additive effect; 0, 1, and 1 for a dominant effect; 0, 0, and 1
for a recessive effect. The relationship between the disease status
and SNP marker and quantitative trait can be expressed using the
equation P(D|X,Y) = exp(c0+c1X+c2Y)/(1+exp(c0+c1X+c2Y)).The
minor allele frequencies (MAFs) of the SNP marker (m1) and disease
allele are both set at 0.3 for a common allele frequency. The values
for b and c parameters in the logistic equation are chosen to fix the
disease incidence rate at 0.05 (Table 1). The value of s2E represents
the residual effect in the regression analysis, which includes the
effect of environmental factors and impact of other genetic loci. The
heterozygous and homozygous odds ratios at the SNP marker range
from 1.2 to 1.4 for a medium-risk model and 1.1 to 1.2 for a low-risk
model.
The genetic variance of the quantitative trait explained by the
SNP marker can be expressed as s2A = 2m1m2a
2,
s2D = (2m1m2ak)
2, in which a= a[1+k(m12m2)] [35]. In this
equation, a and k represent additive and dominant effects of the
SNP marker respectively. In this simulation, the heritability of the
quantitative trait explained by the SNP marker ranges from 0.002
to 0.010, with a step size of 0.002; these numbers are based on the
estimation of common variants effect-size distribution from recent
GWA studies in complex diseases [3]. The type I error rate in the
simulation study was set at 0.01. Additive, dominant, and recessive
effects were simulated at the SNP marker, although the additive
model is the common model assumed in quantitative trait
association analyses. For the medium-risk variants, we simulated
2000 cases and 2000 controls for the additive and dominant
models and 6000 cases and 6000 controls for the recessive model.
For the low-risk variants, we simulated 4000 cases and 4000
controls for the additive and dominant models and 8000 cases and
8000 controls for the recessive model. The analysis program is
coded in R which is available upon request, and we have posted
the code to SourceForge (http://sourceforge.net/p/
modifiedinverse/wiki/Home/).
Disease models in simulations
Figure 6 lists the possible relationships among the disease
susceptibility locus, disease status, and quantitative trait given this
trait is an intermediate phenotype. In model 1, the quantitative
trait and SNP marker are independently associated with the
disease status, and the disease locus is not related to the
quantitative trait. Models 2 and 3 are different from each other
etiologically. Model 2 is a single pathway, whereas model 3 is a
dual pathway between the disease susceptibility locus and disease
status. Mediation analysis can be used to differentiate these two
models [36], but it is impossible to separate models 2 and 3 when
the disease status and quantitative trait are evaluated separately in
the analysis. The results from disease models 1 and 3 were
reported, with the correlation coefficient (r) between the SNP and
disease susceptibility locus increasing from 0 to 0.8 [Figure 1–2].
When r equals 0, the SNP is not associated with the disease locus,
which is the null hypothesis in the simulation.
Analysis of simulated data
Two statistical tests were conducted for the analysis in step 1.
Test 1 is logistic regression analysis of the disease status with the
SNP marker genotype as the covariate, and test 2 is linear
regression analysis of the quantitative trait with adjustment for the
disease status. For the three proposed disease models under the
assumption that the quantitative trait is an intermediate pheno-
type, no association between the SNP and disease status, either
Figure 6. Three possible disease models for one disease locus
with an intermediate phenotype. G, disease susceptibility locus; D,
disease status; QT, quantitative trait (an intermediate phenotype).
doi:10.1371/journal.pone.0046612.g006
Joint Genetic Association with Disease and Trait
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directly or indirectly, means there is no association between the
SNP and quantitative trait and no association between the SNP
and disease status. So test 1 and test 2 are independent under the
null hypothesis. Step 2 is to combine the results from test 1 and 2
using meta-analysis methods. If p1 and p2 are the p values for test 1
and 2, Fisher’s combined probability test can be used to combine
the values to provide an overall p value using the formula
x2 = 22[ln(p1)+ln(p2)], which follows a chi-square distribution with
four degrees of freedom [17].
Two Z-score statistics from tests 1 and 2 were obtained from
score tests, which can be combined using inverse-variance
weighting. Suppose the two Z-scores from tests 1 and 2 are Z1







Under the null hypothesis, Z1 and Z2* are independent
(m1 = m2* = 0).
The estimator of effect size of the SNP from linear regression
analysis of the quantitative trait can be arbitrary depending on the
subjective selection of the measurement unit and normalization
procedure of the trait, which will affect the combination result
from the inverse-variance weighted method. However, if the
quantitative trait is an intermediate phenotype involved in the
development of disease, the estimators of the coefficients for SNP
marker from logistic and linear regression analysis and their
standard errors should be close to a consistent unit, as these are
two different tests for the same associations, i.e., the association
between the SNP marker and disease status. Therefore, Z2* can be
scaled so that it has the same unit as Z1. In the present study, the
standard error of Z2* is scaled so that it is the same as that of Z1,
which is the same as multiplying each quantitative trait by a
constant c, where c = sqrt(s21/s
2
2*). This produces the new Z-
score statistic Z2 = Z1c,N(m2,s21). Let L = bZ1+(12b)Z2, 0,b,1,
when b = 1/2, the variance in L is at its smallest, specifically, 1/
2V(Z1) (Text S1). This creates the new statistic S, which follows a
normal distribution: S = (bZ1+(12b)Z2)/sqrt(1/2V(Z1),N(m3,s23).
In this formula, m3 = 0 under the null hypothesis.
Lung cancer and smoking data with imputed marker
data
The study examined 1154 ever-smokers with lung cancer and
1137 control ever-smokers. The patients and controls were
frequency-matched by age and sex, and they were all of European
origin. Their genotype data came from Illumina HumanHap300
v1.1 BeadChips, and the GWA study results were published in
2008. The genotypes were further imputed using the MACH
(version 1.0.15) [37] with the HapMap 2 database (release 21),
which contained 2,557,253 tagging SNPs. The statistical tests were
conducted on imputed genotypes. Smoking cigarettes per day
(CPD) was used as a quantitative trait in the analysis. We used the
smoking data of CPD as the intermediate phenotype in our
analysis. The box plot and histogram in Figure S1 show the
distribution of the CPD data, and the Q-Q plot in Figure S1 shows
the normality of the CPD data. We used a square root
transformation to normalize the CPD data.
SNPs with a 2log10(p) greater than 5 were regarded as
promising significant SNPs with adjustment for multiple compar-
isons in the association analysis. The normally accepted
2log10(p).8 was not used because of our limited sample size.
Supporting Information
Figure S1 Top, descriptive plots of CPD before aquare
root transformation Bottom, descriptive plots of CPD
after square root transformation.
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Table S1 Type I Error Rates for Medium-Risk Variants
in simulation. Add: additive; Dom: dominant; Rec: recessive.
aDisease locus and quantitative trait are independently associated
with the disease. bQuantitative trait is intermediate between the
disease locus and disease status. cTest 1, logistic regression; test 2,
linear regression; test 3, Fisher’s combined probability test; test 4,
modified inverse-variance weighted method.
(DOC)
Table S2 Type I Error Rates for Low-Risk Variants in
simulation. Add: additive; Dom: dominant; Rec: recessive.
aDisease locus and quantitative trait are independently associated
with the disease. bQuantitative trait is intermediate between the
disease locus and disease status. cTest 1, logistic regression; test 2,
linear regression; test 3, Fisher’s combined probability test; test 4,
modified inverse-variance weighted method.
(DOC)
Table S3 Significant SNPs on Chromosomes 3, 15, and
19 in the Association Analysis. CHR: chromosome; NA: not
available. Test 1, logistic regression; test 2, linear regression
analysis of CPD with adjustment for disease status; test 3, Fisher’s
combined probability test; test 4, modified inversx10-variance
weighted method.
(DOC)
Text S1 Inverse variance weighted combination of Z1
and Z2 has global minimum variance value.
(DOC)
Author Contributions
Conceived and designed the experiments: YFL JH CA. Performed the
experiments: YFL. Analyzed the data: YFL. Contributed reagents/
materials/analysis tools: CA. Wrote the paper: YFL CA.
References
1. Eichler EE, Flint J, Gibson G, Kong A, Leal SM, et al. (2010) Missing
heritability and strategies for finding the underlying causes of complex disease.
Nature 11: 446–450.
2. Frazer AF, Murray SS, Schork NJ, Topol EJ (2009) Human genetic variation
and its contribution to complex traits. Nat Genet 10: 241–251.
3. Park JH, Wacholder S, Gail MH, Peters U, Jacobs KB, et al. (2010) Estimation
of effect size distribution from genome-wide association studies and implications
for future discoveries. Nat Genet 42:570–577.
4. Spencer CCA, Su Z, Donnelly P, Marchini J (2009) Designing genome-wide
association studies: sample size, power, imputation, and the choice of genotyping
chip. PLoS Genet 5(5): e1000477.
5. Marchini J, Howie B (2010) Genotype imputation for genome-wide association
studies. Nat Genet 11: 499–511.
6. Gottesman II, Gould TD (2003) The endophenotype concept in psychiatry:
Etymology and strategic intentions. Am J Psychiatry 160:636–645.
7. Guest editorial (2008) Intermediate phenotype in schizophrenia genetics redux:
is it a no brainer? Mol Psychiatry 13: 233–238.
8. Greenwood TA, Light GA, Swerdlow NR, Radant AD, Braff DL (2012)
Association analysis of 94 candidate genes and Schizophrenia-related endophe-
notypes. PLoS One 7:1 e29630.
9. Simons CJ, Winkel RV, Group (2012) Intermediate phenotype analysis of
patients, unaffected siblings, and healthy controls identifies VMAT2 as a
candidate gene for psychotic disorder and neurocognition. Schizophr Bull 2012
Apr 24.
Joint Genetic Association with Disease and Trait
PLOS ONE | www.plosone.org 8 October 2012 | Volume 7 | Issue 10 | e46612
10. Boyd NF, Rommens JM, Vogt K, Lee V, Hopper JL, et al. (2005)
Mammographic breast density as an intermediate phenotype for breast cancer.
Lancet Oncol 6:798–808.
11. Lindström S, Vachon CM, Li J, Varghese J, Thompson D, et al. (2011)
Common variants in ZNF365 are associated with both mammographic density
and breast cancer risk. Nat Genet 43:185–187.
12. Shulman JM, Chibnik LB, Aubin C, Schneider JA, Bennett DA, et al. (2010)
Intermediate phenotypes Identify divergent pathways to Alzheimer’s disease.
PLoS ONE 5(6): e11244. doi:10.1371/journal.pone.0011244.
13. Franke A, McGovern DPB, Barrett JC, Wang K, Radford-Smith G, et al. (2010)
Genome-wide meta-analysis uncreases to 71 the number of confirmed Crohn’s
disease susceptibility loci. Nat Genet 42.12: 1118–1126.
14. Cooper Jason, Smyth DJ, Smiles AM, Plagno V, Walker NM, et al. (2008)
Meta-analysis of genome-wide association study data identifies additional type I
diabetes risk loci. Nat Genet 40.12: 1399–1401.
15. Chan RCK, Xu T, Heinrichs RW, Yu Y, Wang Y (2009) Neurological soft signs
in schizophrenia: a meta-analysis. Schizophr Bull 36(6):1089–1104.
16. Neelam K, Garg D, Marshall M (2011) A systematic review and meta-analysis of
neurological soft signs in relatives of people with schizophrenia. BMC Psychiatry
11:139.
17. Fisher RA, Thomson JA (1918) The correlation between relatives on the
supposition of Mendelian inheritance. Proceedings of the Royal Society of
Edinburgh 52:399–433.
18. Abecasis GR, Willer C, Li Y (2010) METAL: fast and efficient meta-analysis of
genomewide association scans. Bioinformatics 26(17): 2190–2191.
19. Liu JZ, Tozzi F, Waterworth DM, Pillai SG, Muglia P, et al. (2010) Meta-
analysis and imputation refines the association of 15q25 with smoking quantity.
Nat Genet 42.5: 436–442.
20. Amos CI, Wu X, Broderick P, Gorlov IP, Gu J, et al. (2008) Genome-wide
association scan of tag SNPs identifies a susceptibility locus for lung cancer at
15q25.1. Nat Genet 40.5:616–622.
21. Spitz MR, Amos CI, Dong Q, Lin J, Wu X (2008) The CHRNA5-A3 region on
chromosome 15q24–25.1 is a risk factor both for nicotine dependence and for
lung cancer. J Natl Cancer Inst 100(21):1552–1556.
22. The Tobacco and Genetics Consortium (2010) Genome-wide meta-analyses
identify multiple loci associated with smoking behavior. Nat Genet 42(5):441–
449.
23. Hung RJ, McKay JD, Gaborieau V, Boffetta Paolo, Hashibe M, et al. (2008) A
susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor
subunit genes on 15q25. Nature 452:633–637.
24. Celedón JC, Lange C, Raby BA, Litonjua AA, Palmer Lj, et al. (2004) The
transforming growth factor-b1 (TGFB1) gene is associated with chronic
obstructive pulmonary disease (COPD). Hum Mol Genet 13(15):1649–1656.
25. Park KH, Lo Han SG, Wahng YM, Lee HJ, Yoo YD, et al. (2006) Single
nucleotide polymorphisms of the TGFB1 gene and lung cancer risk in a Korean
population. Cancer Genet Cytogenet 169(1):39–44.
26. Braga E, Senchenko V, Bazov I, Loginov W, Liu J, et al. (2002) Critical tumor-
suppressor gene regions on chromosome 3q in major human epithelial
malignancies: allelotyping and quantitative real-time PCR. Int J Cancer
100:534–541.
27. Dasgupta S, Chakraborty SB, Roy A, Roychowdhury S, Panda CK (2003)
Differential deletions of chromosome 3p are associated with the development of
uterine cervical carcinoma in Indian patients. Mol Pathol 56(5):263–269.
28. Centers for Disease Control and Prevention website. Available: http://www.cdc.
gov/genomics/population/file/print/genvar/table_variantbypathway.pdf. Ac-
cessed 2012 Sep 22.
29. Thorgeirsson TE, Geller F, Sulem P, Rafnar T, Wiste A, et al. (2008) A variant
associated with nicotime dependence, lung cancer and peripheral arterial
disease. Nature 452:638–642.
30. VanderWeele TJ, Asomaning K, Tchetgen EJ, Han Y, Spitz MR, et al. (2012)
Genetic variants on 15q25.1, smoking, and lung cancer: an assessment of
mediation and interaction. Am J Epidemiol 175(10):1013–1020.
31. Wang J, Spitz MR, Amos CI, Wilkinson AV, Wu X, et al. (2010) Mediating
effects of smoking and chronic obstructive pulmonary disease on the relation
between the CHRNA5-A3 genetic locus and lung cancer risk. Cancer
116(14):3458–62.
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